Department of Comprehensive Medical, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, P.R. China.
Department of Clinical Laboratory, Nanjing Jiangbei Hospital Affiliated to Nantong University, 552 Geguan Road, Jiangbei New District, Nanjing, Jiangsu, 210048, P.R. China.
BMC Pulm Med. 2023 Aug 18;23(1):305. doi: 10.1186/s12890-023-02600-7.
The objective of this study was to investigate the association between white blood cell count to hemoglobin ratio (WHR) and risk of in-hospital mortality in patients with lung cancer.
In this retrospective cohort study, the medical records of patients with lung cancer were retrieved from the electronic ICU (eICU) Collaborative Research Database between 2014 and 2015. The primary outcome was in-hospital mortality. The secondary outcome was the length of stay in intensive care unit (ICU). The cut-off value for the WHR was calculated by the X-tile software. The Cox model was applied to assess the association between WHR and in-hospital mortality among patients with lung cancer and the linear regression model was used to investigate the association between WHR and length of ICU stay. Subgroup analyses of age (< 65 years or > = 65 years), Acute Physiology and Chronic Health Evaluation (APACHE) score (< 59 or > = 59), gender, ventilation (yes or no), and vasopressor (yes or no) in patients with lung cancer were conducted.
Of the 768 included patients with lung cancer, 153 patients (19.92%) died in the hospital. The median total follow-up time was 6.88 (4.17, 11.23) days. The optimal cut-off value for WHR was 1.4. ICU lung cancer patients with WHR > = 1.4 had a significantly higher risk of in-hospital mortality [Hazard ratio: (HR): 1.65, 95% confidence interval (CI): 1.15 to 2.38, P = 0.007) and length of stay in ICU (HR: 0.63, 0.01, 95% CI: 1.24 to 0.045, P = 0.045). According to the subgroup analysis, WHR was found to be associated with in-hospital mortality in patients with higher APACHE score (HR: 1.60, 95% CI: 1.06 to 2.41, P = 0.024), in male patients (HR: 1.87, 95% CI: 1.15 to 3.04, P = 0.012), and in patients with the treatment of ventilation (HR: 2.33, 95% CI: 1.49 to 3.64, P < 0.001).
This study suggests the association between WHR and risk of in-hospital mortality in patients with lung cancer and length of stay, which indicates the importance of attention to WHR for patients with lung cancer.
本研究旨在探讨白细胞计数与血红蛋白比值(WHR)与肺癌患者住院死亡率之间的关系。
本回顾性队列研究从 2014 年至 2015 年的电子 ICU(eICU)协作研究数据库中检索了肺癌患者的病历。主要结局是住院死亡率。次要结局是 ICU 住院时间。WHR 的截断值通过 X-tile 软件计算。采用 Cox 模型评估肺癌患者 WHR 与住院死亡率之间的关系,采用线性回归模型探讨 WHR 与 ICU 住院时间之间的关系。对年龄(<65 岁或 > =65 岁)、急性生理学和慢性健康评估(APACHE)评分(<59 或 > =59)、性别、通气(是或否)和血管加压剂(是或否)的肺癌患者进行亚组分析。
纳入的 768 例肺癌患者中,153 例(19.92%)在医院死亡。中位总随访时间为 6.88(4.17,11.23)天。WHR 的最佳截断值为 1.4。WHR > =1.4 的 ICU 肺癌患者住院死亡率显著升高[风险比(HR):1.65,95%置信区间(CI):1.15 至 2.38,P =0.007]和 ICU 住院时间(HR:0.63,0.01,95%CI:1.24 至 0.045,P =0.045)。根据亚组分析,WHR 与 APACHE 评分较高的患者的住院死亡率相关(HR:1.60,95%CI:1.06 至 2.41,P =0.024),与男性患者(HR:1.87,95%CI:1.15 至 3.04,P =0.012),以及接受通气治疗的患者(HR:2.33,95%CI:1.49 至 3.64,P <0.001)。
本研究提示白细胞计数与血红蛋白比值与肺癌患者住院死亡率及住院时间相关,表明肺癌患者对白细胞计数与血红蛋白比值的关注具有重要意义。